Inflammation as a central mechanism in Alzheimer's disease Tập 4 Số 1 - Trang 575-590 - 2018
Jefferson W. Kinney, Shane M. Bemiller, Andrew S. Murtishaw, Amanda M. Leisgang, Arnold Salazar, Bruce T. Lamb
AbstractAlzheimer's disease (AD) is a progressive neurodegenerative disorder
that is characterized by cognitive decline and the presence of two core
pathologies, amyloid β plaques and neurofibrillary tangles. Over the last
decade, the presence of a sustained immune response in the brain has emerged as
a third core pathology in AD. The sustained activation of the brain's resident
macrophages (micro... hiện toàn bộ
Alzheimer's disease drug development pipeline: 2018 Tập 4 Số 1 - Trang 195-214 - 2018
Jeffrey L. Cummings, Garam Lee, Aaron Ritter, Kate Zhong
AbstractIntroductionTreatments for Alzheimer's disease (AD) are needed due to
the growing number of individuals with preclinical, prodromal, and dementia
forms of AD. Drug development for AD therapies can be examined by inspecting the
drug development pipeline as represented on
clinicaltrials.gov.MethodsClinicaltrials.gov was assessed as of January 30, 2018
to determine AD therapies represented in... hiện toàn bộ
Alzheimer's disease drug development pipeline: 2017 Tập 3 Số 3 - Trang 367-384 - 2017
Jeffrey L. Cummings, Garam Lee, Travis Mortsdorf, Aaron Ritter, Kate Zhong
AbstractIntroductionThere is an urgent need to develop new treatments for
Alzheimer's disease (AD) and to understand the drug development process for new
AD therapies.MethodsWe assessed the agents in the AD pipeline as documented in
clinicaltrials.gov for phase I, phase II, and phase III, accessed
1/5/2017.ResultsThere are 105 agents in the AD treatment development pipeline,
of which 25 agents are... hiện toàn bộ
Sedentary behavior as a risk factor for cognitive decline? A focus on the influence of glycemic control in brain health Tập 3 Số 3 - Trang 291-300 - 2017
Michael J. Wheeler, Paddy C. Dempsey, Megan S. Grace, Kathryn A. Ellis, Paul A. Gardiner, Daniel J. Green, David W. Dunstan
AbstractCognitive decline leading to dementia represents a global health burden.
In the absence of targeted pharmacotherapy, lifestyle approaches remain the best
option for slowing the onset of dementia. However, older adults spend very
little time doing moderate to vigorous exercise and spend a majority of time in
sedentary behavior. Sedentary behavior has been linked to poor glycemic control
and... hiện toàn bộ
Amyloid‐associated increases in longitudinal report of subjective cognitive complaints Tập 4 - Trang 444-449 - 2018
Rebecca E. Amariglio, Rachel F. Buckley, Elizabeth C. Mormino, Gad A. Marshall, Keith A. Johnson, Dorene M. Rentz, Reisa A. Sperling
AbstractIntroductionTo investigate whether baseline subjective cognitive
complaints (SCCs) predict longitudinal decline on neuropsychological testing and
whether SCC increases longitudinally, in the setting of high levels of amyloid
burden.MethodsTwo hundred seventy‐nine clinically normal older participants
(mean age = 73.7 ± 6.1 years) from the Harvard Aging Brain Study, a cohort of
community‐dwe... hiện toàn bộ
Accelerating drug development for Alzheimer's disease through the use of data standards Tập 3 - Trang 273-283 - 2017
Jon Neville, Steve Kopko, Klaus Romero, Brian Corrigan, Bob Stafford, Elizabeth LeRoy, Steve Broadbent, Martin Cisneroz, Ethan Wilson, Eric Reiman, Hugo Vanderstichele, Stephen P. Arnerić, Diane Stephenson
AbstractIntroductionThe exceedingly high rate of failed trials in Alzheimer's
disease (AD) calls for immediate attention to improve efficiencies and learning
from past, ongoing, and future trials. Accurate, highly rigorous standardized
data are at the core of meaningful scientific research. Data standards allow for
proper integration of clinical data sets and represent the essential foundation
for... hiện toàn bộ
No synergistic effect of subtherapeutic doses of donepezil and EVP‐6124 in healthy elderly subjects in a scopolamine challenge model Tập 5 - Trang 89-98 - 2019
Anne Catrien Baakman, Ricardo Alvarez-Jimenez, Gordon Loewen, Marieke L. de Kam, Karen Broekhuizen, Dana C. Hilt, Geert Jan Groeneveld
AbstractIntroductionDonepezil is a widely used cholinesterase inhibitor in the
management of Alzheimer's disease. Despite large‐scaled evidence for its
efficacy, elevated peripheral ACh levels often lead to side effects and are dose
limiting. The present exploratory study is designed to determine the
potentiation of the effects of donepezil by cotreatment with EVP‐6124, an
alpha‐7 nicotinic agonis... hiện toàn bộ
A single systemic inflammatory insult causes acute motor deficits and accelerates disease progression in a mouse model of human tauopathy Tập 5 - Trang 579-591 - 2019
Megan Torvell, David W. Hampton, Peter Connick, Alasdair M.J. MacLullich, Colm Cunningham, Siddharthan Chandran
AbstractIntroductionNeuroinflammation, which contributes to neurodegeneration,
is a consistent hallmark of dementia. Emerging evidence suggests that systemic
inflammation also contributes to disease progression.MethodsThe ability of
systemically administered lipopolysaccharide (LPS ‐ 500 μg/kg) to effect acute
and chronic behavioural changes in C57BL/6 and P301S tauopathy mice was
assessed. Marker... hiện toàn bộ
Estrogen activates Alzheimer's disease genes Tập 5 - Trang 906-917 - 2019
Abhirami Ratnakumar, Samuel E. Zimmerman, Bryen A. Jordan, Jessica C. Mar
AbstractIntroductionWomen are at increased risk for Alzheimer's disease (AD),
but the reason why remains unknown. One hypothesis is that low estrogen levels
at menopause increases vulnerability to AD, but this remains unproven.MethodsWe
compared neuronal genes upregulated by estrogen in ovariectomized female rhesus
macaques with a database of >17,000 diverse gene sets and applied a rare variant
bu... hiện toàn bộ
Randomized, controlled, proof‐of‐concept trial of MK‐7622 in Alzheimer's disease Tập 4 - Trang 173-181 - 2018
Tiffini Voss, Jerry Li, Jeffrey Cummings, Martin Farlow, Christopher Assaid, Samar Froman, Heather Leibensperger, Linda Snow-Adami, Kerry Budd McMahon, Michael Egan, David Michelson
AbstractIntroductionWe evaluated the selective M1 muscarinic positive allosteric
modulator, MK‐7622, as adjunctive cognitive enhancing therapy in individuals
with Alzheimer's disease.MethodsA randomized, double‐blind, proof‐of‐concept
trial was performed. Participants with mild‐to‐moderate Alzheimer's disease,
being treated with an acetylcholinesterase inhibitor, were randomized 1:1 to
45 mg of MK... hiện toàn bộ